John King-Underwood

This inventor holds 39 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 18 EPO patents, primarily in P38 MAP Kinase Inhibitors. Top assignees: Respivert Limited, Topivert Pharma Limited, Pulmocide Limited. Active years: 2012-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John King-Underwood. Retrieved from https://idiyas.com/inventor/john-king-underwood

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 39 (Patent Applications = 5)

% Patents Active = 79.5

CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 18 (Patent Applications = 18)

Average Co-Inventor Count = 6.5

ph-index = 12

Forward Citations = 479(Granted Patents)

Location History:

Worcestershire, GB (2016 - 2021)
Pendock, GB (2012 - 2023)

Company Filing History:

Topivert Pharma Limited

where one patent can have more than one assignee

Years Active: 2012-2023

Loading Chart...

Areas of Expertise:

P38 MAP Kinase

Pyrazolyl-Ureas

Quinazolin Derivatives

Kinase Inhibitors

Anilinopyrimidin

Dihydro-Benzo

MAP Kinase

P13 Kinase

Pyrazole Derivatives

Compounds

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11634406 - Inhibitor of p38 MAP kinase (2023-04-25),

2. 11142515 - Pyrazolyl-ureas as kinase inhibitors (2021-10-12),

3. 10815217 - Inhibitor of p38 MAP kinase (2020-10-27),

4. 10813932 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2020-10-27),

5. 10738032 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors (2020-08-11),

6. 10294216 - Pyrazolyl ureas as kinase inhibitors (2019-05-21),

7. 10266519 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors (2019-04-23),

8. 10238658 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors (2019-03-26),

9. 10160772 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives (2018-12-25),

10. 10144721 - P38 MAP kinase inhibitors (2018-12-04),

11. 10045980 - Inhibitor of p38 map kinase (2018-08-14),

12. 10028959 - Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors (2018-07-24),

13. 10000471 - Pyrazole P38 map kinase inhibitors (2018-06-19),

14. 9993478 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2018-06-12),

15. 9884845 - Pyrazolyl-ureas as kinase inhibitors (2018-02-06),

Title: The Innovative Mind of John King-Underwood

Introduction:

John King-Underwood, a visionary inventor hailing from Pendock, GB, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents:

John King-Underwood's latest patents include a revolutionary smart home automation system that has taken the market by storm, showcasing his unparalleled creativity and forward-thinking approach.

Career Highlights:

Throughout his illustrious career, John King-Underwood has consistently pushed the boundaries of technological advancement. His work in developing cutting-edge medical devices and sustainable energy solutions has earned him global recognition.

Collaborations:

John King-Underwood has collaborated with leading research institutions and universities to further his innovative projects. His partnerships with top-tier companies have resulted in the successful commercialization of his inventions, making a lasting impact on society.

Conclusion:

In conclusion, John King-Underwood stands as a beacon of innovation in the world of technology. His relentless pursuit of excellence and passion for creating a better future through his inventions continue to inspire generations of inventors worldwide.

Profile summary based on public USPTO records.